UNICREDIT BANK/CALL/MODERNA/180/0.1/15.01.25 | Real-time BOERSE MUENCHEN 03:40:39 2024-05-23 am EDT | ||
| 2.24 EUR | +7.18% |
|
| Current month | +294.34% | ||
| 1 month | +397.62% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 24-05-23 | 2.24 | +7.18% |
| 24-05-22 | 2.09 | +67.20% |
| 24-05-21 | 1.25 | +7.76% |
| 24-05-20 | 1.16 | +30.34% |
| 24-05-17 | 0.89 | -1.11% |
Real-time BOERSE MUENCHEN
Last update May 23, 2024 at 03:40 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
UniCredit
|
| WKN | HD31XE |
| ISIN | DE000HD31XE3 |
| Date issued | 2024-02-26 |
| Strike | 180 $ |
| Maturity | 2025-01-15 (238 Days) |
| Parity | 10 : 1 |
| Emission price | 0.38 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.24 € |
|---|---|
| Lowest since issue | 0.29 € |
| Spread | 0.06 € |
| Spread % | 2.68% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
163.3
USD
Average target price
138.5
USD
Spread / Average Target
-15.19%
- Stock Market
- Warrants
- Warrant
